ARICEPT safely and effectively. See full prescribing information for ARICEPT Tablets and ARICEPT Orally Disintegrating Tablets (ODT). ARICEPT

-----------------------WARNINGS AND PRECAUTIONS------------------­  Cholinesterase inhibitors are likely to exaggerate succinylcholine­ type muscle relaxation during anesthesia (5.1).  Cholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block (5.2).  ARICEPT can cause vomiting. Patients should be observed closely at initiation of treatment and after dose increases (5.3).  Patients should be monitored closely for symptoms of active or occult gastrointestinal (GI) bleeding, especially those at increased risk for developing ulcers (5.4).  The use of ARICEPT in a dose of 23 mg once daily is associated with weight loss (5.5).  Cholinomimetics may cause bladder outflow obstructions (5.6).  Cholinomimetics are believed to have some potential to cause generalized convulsions (5.7).  Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease (5.8).